Avid Bioservices Inc (CDMO)

[biopharm]

Avid Bioservices receiving royalties milestones etc etc etc from PS Targeting IP from Oncologie Inc and we wait for exosomes news out of UTSWM and any other biomarker driven developments that require PS Targeting

Many thought it was nonsense in how corrupt Big Pharma can be and how some stop at nothing to control drug development such as PS Targeting IP

PS Targeting has been in the works for many years starting with the late Dr Phil Thorpe and many twists and turns since ... we have had multiple sabotaged like trials, have had Dr Jack West hit piece articles against Peregrine to Ex Bristol Myer Squibb Robert H Schwartz that wrote the 'throw in the towel ..' hit piece on Peregrine to Jim Cramer want a be Adam F that had many a hit piece articles on Peregrine ... leading to historical control arm Docetaxel that Ex CEO Steve King publicly had words of disbelief ...

So so much more ....and many wondered what federal investigations were ongoing and now, they are dropping left and right from key institutions that had access to PS Targeting research data

I know am bewildered in how John Springs Stafford could have been left out of the loop ...along with Oncologie Inc backers ...especially with Federal Investigations active

US President Trump officially says they will cure cancer / Alzheimer's etc ....same positive remarks from Joe Biden ...and I say it is no coincidence that for the first time in history the confidence is building

IIS building in Avid as well... as this is truly not even close to the trading like that of Peregrine past.

Lots of MOA sound similar to that of Bavituximab / PS Targeting

Could a select few BPs corner get to market first with PS Targeting and promise CDMO astronomical type CDMO business based upon PS Targeting IP asset research etc ?

______

July 11, 2019

Report: Cornell’s ties to Qatar and China under federal investigation

The Department of Education is alleging that Cornell University has failed to disclose foreign gifts and contracts from Qatar and China, according to a report by the Associated Press.

The department, through letters to university presidents, alleged that Cornell, along with Texas A&M, Georgetown University and Rutgers University, did not tell federal officials about particular gifts and contracts. Two universities’ letters have been released publicly, while two more are expected to be released sometime next week.


Cornell spokesman John Carberry shared the following statement: “On July 3, Cornell University received a letter from the Department of Education, requesting records related to previously submitted federally required reports. Cornell takes our reporting requirements seriously. We are currently reviewing the request and plan to fully cooperate with federal officials in this effort.”

The University has received over $65 million in contracts and gifts from Qatar between 2012 and 2018, according to data aggregated by the Department of Education. Universities are required to report contracts and gifts greater than $250,000 per year. Cornell also notes that it has a “significant international educational presence, including Weill Cornell Medical College’s campus in Doha, Qatar,” in its 2017 990 tax filing.

“Weill Cornell Medicine – Qatar has trained and graduated hundreds of young physicians from the Middle East, Asia and many other countries (including the U.S.), enabling the ongoing transformation of patient care, biomedical research and quality of life in the region and around the world,” continued Carberry’s statement.

Leaderboard 2


Cornell has also received $12.5 million worth of contracts and gifts based in China. Over $5 million of that money was from contracts with Huawei, a technology company listed by the federal government as one that is denied sensitive technology because it is a danger to national security. The $5.3 million payment, spread over two research contracts in 2017, was the largest payout to an American university in the last six years, the Cornell Sun reported.

Cornell’s Qatar campus was established in January 2001, and has since operated in a relationship with Weill Cornell Medicine, which is based in Cornell’s New York City campus. It is one of six U.S. schools that have branches in Qatar.


________________

July 11, 2019


The Cytokine TNF Promotes Transcription Factor SREBP Activity and Binding to Inflammatory Genes to Activate Macrophages and Limit Tissue Repair

Anthony Kusnadi 6
Sung Ho Park 6
Ruoxi Yuan
Tania Pannellini
Eugenia Giannopoulou
David Oliver
Theresa Lu
Kyung-Hyun Park-Min
Lionel B. Ivashkiv 7

Published:July 11, 2019

Highlights

•
TNF induces late-phase activation of SREBP2 and cholesterol genes in macrophages
•
SREBP2 binds and activates inflammatory target genes in TNF-stimulated macrophages
•
Inhibition of the TNF-SREBP axis promotes M2-like polarization and wound healing
•
The TNF-SREBP axis is an attractive therapeutic target for promoting tissue repair
Summary

Cytokine tumor necrosis factor (TNF)-mediated macrophage polarization is important for inflammatory disease pathogenesis, but the mechanisms regulating polarization are not clear. We performed transcriptomic and epigenomic analysis of the TNF response in primary human macrophages and revealed late-phase activation of SREBP2, the master regulator of cholesterol biosynthesis genes. TNF stimulation extended the genomic profile of SREBP2 occupancy to include binding to and activation of inflammatory and interferon response genes independently of its functions in sterol metabolism. Genetic ablation of SREBP function shifted the balance of macrophage polarization from an inflammatory to a reparative phenotype in peritonitis and skin wound healing models. Genetic ablation of SREBP activity in myeloid cells or topical pharmacological inhibition of SREBP improved skin wound healing under homeostatic and chronic inflammatory conditions. Our results identify a function and mechanism of action for SREBPs in augmenting TNF-induced macrophage activation and inflammation and open therapeutic avenues for promoting wound repair.

https://www.cell.com/immunity/pdfExtended/S1074-7613(19)30275-4